Traitement par isotrétinoïne et interféron alpha 2a de la maladie de Kaposi associée au SIDA

Phase II pilot trial on the efficacy and tolerance of the combination 13-cis-retinoic acid plus interferon α 2a in AIDS-related Kaposi's sarcoma. Using criterions described by known, neither complete nor partial response was achieved, but clinical and histological changes were noted. Tolerance of the combination was good.